National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements - Wikidata - thesis-toulmin - TriplyDB

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements

http://www.wikidata.org/entity/Q41469418

about

"OMIC" tumor markers for breast cancer: A review Circulating biomarkers in advanced renal cell carcinoma: clinical applications Sources of bias in specimens for research about molecular markers for cancer Standards affecting the consistency of gene expression arrays in clinical applications.Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box.Cancer biomarkers: can we turn recent failures into success?The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer.A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Taking a new biomarker into routine use--a perspective from the routine clinical biochemistry laboratory Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay.Cancer and the microbiome: potential applications as new tumor biomarker.HER2-directed therapy: current treatment options for HER2-positive breast cancer.Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence.Paraneoplastic neurological syndromes: severe neurological symptoms resulting from relatively benign or occult tumours-two case reports.Detection of OSR2, VAV3, and PPFIA3 Methylation in the Serum of Patients with Gastric Cancer.Methylated DNA and microRNA in body fluids as biomarkers for cancer detection.From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.Predictive Value of Carcinoembryonic and Carbohydrate Antigen 19-9 Related to Some Clinical, Endoscopic and Histological Colorectal Cancer Characteristics.Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine.Pharmacogenetics in dermatology: a patient-centered update.Methylated DNA for monitoring tumor growth and regression: how do we get there?Clinical applications of MS-based protein quantification.The role of neurotensin as a novel biomarker in the endoscopic screening of high-risk population for developing colorectal neoplasia.Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.Oxibendazole inhibits prostate cancer cell growth.Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study.Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.Circular RNA maps paving the road to biomarker development?Is serum human epididymis protein 4 ready for prime time?Evolution of proteomic biomarker for chronic liver disease: Promise into reality.

P2860

Q26773092-2016B342-3282-4F9B-BCD0-AE3B205A498C Q27023770-E28A92E9-F453-44DC-BB11-2495391667F4 Q33628822-8969ECB7-EA30-466E-BB1F-024665CFCFF7 Q33780759-5F6EAD38-895E-4C4B-88AD-9F082389828E Q33876854-30506A2B-1721-4523-BC39-A760D42BB592 Q34176379-38176769-5DEE-4BB9-9919-E3F14DC476E2 Q34365135-A6ACCDAD-281B-4298-AEBF-F555F18C627F Q34603514-E506E67B-E042-458B-98D4-AB442CDAAE3F Q34672941-D08559D8-3974-41B4-9121-5522CD4F7DBA Q34694790-34EF8B32-8133-4902-A574-A9F0D6E91C92 Q34761258-C914F858-1130-4FD8-BBAE-C2EA6B090F1F Q35508820-C77B77F7-7871-4A07-9900-9010A1063690 Q35551522-8ADDB3C4-F56D-44D8-BE86-3F9A690F2FC6 Q36418652-CB477100-498C-4C29-B0DF-05DF1FA46A4D Q36801659-8D6621DF-3557-49B1-93F6-CF626C1C129B Q36819379-0BF8EF94-DD6C-463F-89A7-A7A91A5DB566 Q36913739-72DE1E75-E2AC-4A40-8D00-795B5F2B55AC Q37154789-C15EFB9E-335B-4D62-A8DC-3B52BDE35AEB Q37363395-EB593B62-98C8-4F79-BD60-3F394251F7FA Q37694962-9E732789-EBA6-4582-95CE-ECBD3DE36A57 Q38100809-954D41CA-E985-4BF7-83F1-2361342C9AC6 Q38115822-BCA60B15-F16D-434F-8AB9-831C10247A8C Q38194584-1D849220-3126-4D66-8733-B44BF930530E Q38802991-D34E9D30-41F8-496E-BBF3-0320CB99A074 Q41474497-29C37EC8-120A-4C5C-AC24-5E9A50D5BF00 Q48594906-8BE4D7A3-6D92-4661-A625-9B168338DF01 Q49511046-C2270FB4-9208-4B40-9177-36BB9CBEE036 Q49530055-FCF16E4B-624E-4B40-90FF-C2BA8912E21E Q49975387-02CFB74B-AD14-4742-AEDB-F39692C88A6C Q50001301-E81999CC-486B-4236-93C9-66697E3A36BA Q50079351-3E2A7D2D-EDFD-404B-93BB-ED066857B595 Q50773867-0C5A598B-748F-4A6E-A395-F6C8E85CD193 Q55091571-806070B9-04AB-4778-B928-F52782AAEA34

P2860

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements

http://www.wikidata.org/entity/Q41469418

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

National Academy of Clinical B ...... practice: quality requirements

@en

type

label

National Academy of Clinical B ...... practice: quality requirements

@en

prefLabel

National Academy of Clinical B ...... practice: quality requirements

@en

P1433

Q41469418-0B1BF27F-316C-4600-81E5-87BA7399F55D

P1476

Q41469418-A8894243-0EB9-4409-B89F-A75F69408FED

P2093

Q41469418-0B63A0FD-B05A-4BEA-9F97-182B97CE9CFE

Q41469418-0C7DB15E-0921-4B66-86B8-4027DBA1DD71

Q41469418-2D7FBC3B-2DCB-4094-8DF6-EEC37F16CCCC

Q41469418-41E9D2B3-7E4E-417F-AA03-7263AB9EC43A

Q41469418-4D1FADDB-A6A3-44FD-870C-271C4E0B024E

Q41469418-6B9DCA78-9900-4F2E-B9C1-8946484F4241

Q41469418-78689CA4-DEED-4FE2-BBB4-D04A2066A445

Q41469418-882D7780-6CF3-47D6-827A-F54687515B55

Q41469418-9F02D42E-1773-48A0-B897-EBA03913A820

Q41469418-BBC83372-310A-4ADF-A848-BEFEE3A51E33

P2860

Q41469418-06B7F185-7593-4DED-9852-62AC91F0C27A

Q41469418-11C89449-2DEE-4482-96BC-AA548D643C8E

Q41469418-15A38AC5-6C64-447E-962A-3A55B0DF88E4

Q41469418-1BE39C54-6310-45A1-9C3E-FCCA0D4C1335

Q41469418-222DDA9E-1B52-400F-957D-3DF13585BD15

Q41469418-29C4E523-5B8A-4936-8CC4-973E1E4B33D2

Q41469418-342A7C2C-6F6F-49AA-B441-77C2F3D11184

Q41469418-3744CACA-52F2-486E-A9E8-5EDA3513FF9A

Q41469418-48AEA00D-EB32-40F6-9189-2B4C4E363D40

Q41469418-5624830B-9B47-45DE-A996-52FCF0F97785

P304

Q41469418-45FD853A-ABED-4C40-81CC-A56BB5FAB109

P31

Q41469418-B3408FC8-6417-48C2-830C-D347927640E2

P356

Q41469418-57907743-FD16-44AF-94EB-FF85E740CCDD

P407

Q41469418-FA909B22-72A9-49E2-91F0-74E4E4954CF5

P433

Q41469418-EBDBAEDE-1FD8-4BD6-8D10-619CD3857852

P478

Q41469418-D1901F6C-E879-4C71-92E6-27957EFA6495

P50

Q41469418-4C5C75DC-9865-4D76-AEAE-1BB1971B845D

P577

Q41469418-031A3AC2-6E89-41FD-AFB8-96D9A825EAF9

P5875

Q41469418-00EC4DC6-34A6-4F22-BE8F-83D7B656F749

P698

Q41469418-01FAD86B-BDFF-407B-9DBC-4CDE1EB5DFDD

P932

Q41469418-83B4735D-AB11-4721-849B-D2CA4827F15E

P356

CLINCHEM.2007.094144

P1433

Clinical Chemistry

P1476

National Academy of Clinical B ...... practice: quality requirements

@en

P2093

Barry R Hoffman

http://www.w3.org/2001/XMLSchema#string

Catharine M Sturgeon

http://www.w3.org/2001/XMLSchema#string

Daniel F Hayes

http://www.w3.org/2001/XMLSchema#string

Daniel W Chan

http://www.w3.org/2001/XMLSchema#string

Elena van der Merwe

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hammond

http://www.w3.org/2001/XMLSchema#string

Emmanuel F Petricoin

http://www.w3.org/2001/XMLSchema#string

Györg Söletormos

http://www.w3.org/2001/XMLSchema#string

Lance A Liotta

http://www.w3.org/2001/XMLSchema#string

Manfred Schmitt

http://www.w3.org/2001/XMLSchema#string

P2860

An investigation into the human serum "interactome"

Expression monitoring by hybridization to high-density oligonucleotide arrays

Gene expression profiling predicts clinical outcome of breast cancer

A gene-expression signature as a predictor of survival in breast cancer

Quantitative monitoring of gene expression patterns with a complementary DNA microarray

Multi-analyte immunoassay

Mass spectrometry-based clinical proteomics.

Determination of tumor markers in serum. Pitfalls and good practice.

The need for standards, not guidelines, in biological data reporting and sharing.

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

P304

e1-e10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1373/CLINCHEM.2007.094144

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Eleftherios P. Diamandis

P577

2008-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5245629

http://www.w3.org/2001/XMLSchema#string

P698

18606634

http://www.w3.org/2001/XMLSchema#string

P932

5564312

http://www.w3.org/2001/XMLSchema#string